Physician profile
Robert Spira
NPI 1902877525
$16,252.34
in general payments reported to CMS, 2019-2025
32 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,971 · 2020: $2,737 · 2021: $421 · 2022: $522 · 2023: $1,128 · 2024: $448 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.22 |
| Education | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,165.92 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $607.05 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $492.48 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $282.40 | 2020-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.81 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $175.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $168.02 | 2023-2024 | Exalt Model D |
| Pfizer INC. | $142.71 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $113.45 | 2019 | |
| Ardelyx, INC. | $92.21 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $85.19 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $71.60 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $57.87 | 2021-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $54.18 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $52.64 | 2019-2023 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $41.82 | 2022 | |
| Lilly USA, LLC | $41.60 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $41.39 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $31.66 | 2025 | Terlivaz |
| Medtronic, INC. | $29.96 | 2023 | Bravo, Gi Genius |
| Ironwood Pharmaceuticals, INC | $27.50 | 2019 | |
| Ucb, INC. | $27.03 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $24.29 | 2025 | |
| Micro-Tech Endoscopy USA, INC. | $23.03 | 2024 | Abc Balloons |
| Novo Nordisk INC | $20.37 | 2025 | Wegovy |
| Exact Sciences Corporation | $20.10 | 2025 | Cologuard Collection Kit |
| Organon LLC | $18.47 | 2023 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $18.25 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $16.19 | 2025 | Zenpep |
| Capsovision, INC. | $15.03 | 2025 | Capsocam Plus |
| Otsuka America Pharmaceutical, INC. | $12.76 | 2019 | |
| Shionogi INC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.